Praxis Precision Medicines, Inc.
PRAX
Hisse Senetlerindeki Sıralama
#2615
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Hisse Fiyatı
$260.52
Son senkronizasyon: 2026-10-19
Piyasa Değeri
$7.27B
Değişim (1 gün)
7.76%
Değişim (1 yıl)
48.81%
Ülke
US
Ticaret Praxis Precision Medicines, Inc. (PRAX)
Kategori
Healthcare
Praxis Precision Medicines, Inc. (PRAX) için kazanç
Jun 2026 itibarıyla kazanç TTM: $-339.13M
Praxis Precision Medicines, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-339.13M'dir. 2023 yılında şirket $-123.28M kazanç elde etti, bu 2022 yılındaki $-214.03M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Praxis Precision Medicines, Inc. için kazanç geçmişi 2018 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-339.13M | 85.50% |
| 2024 | $-182.82M | 48.30% |
| 2023 | $-123.28M | -42.40% |
| 2022 | $-214.03M | 28.11% |
| 2021 | $-167.06M | 170.20% |
| 2020 | $-61.83M | 73.69% |
| 2019 | $-35.60M | 34.82% |
| 2018 | $-26.40M | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -1,655.44% |
US
|
|
| $-3.09B | 810.28% |
US
|
|
| $-4.02B | 1,084.28% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -675.20% |
NL
|
